Clinical trials: Glioblastoma, IDH-Wildtype
Primary Glioblastoma
Carbon Ion Radiotherapy for Primary Glioblastoma
Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ). Radiation is delivered up to a total dose of 60 Gy using photons.
- Trial name
- CLEOPATRA (NCT01165671)
- Testing
- Carbon Ion Radiotherapy, Proton Radiotherapy
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University Hospital Heidelberg
Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype
WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous…
- Conditions
- Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Central Nervous System
- Trial name
- NCT04197934
- Testing
- Biospecimen Collection - blood samples, Biospecimen Collection - CSF samples, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mayo Clinic
Malignant Gliomas
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months.
- Trial name
- NCT00463073
- Testing
- Cetuximab, Bevacizumab, Irinotecan
- Where
- 3 sites in Denmark
- Volunteers
- 32 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal.
- Conditions
- Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer, Recurrent Tumor
- Trial name
- NCT07416188
- Testing
- LMP744, Conventional Surgery or Biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Relapsed Cancer, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol).
- Trial name
- GBrecurr (NCT06430424)
- Testing
- Relapsed glioblastoma
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Bordeaux
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Feasibility of ONCOhabitats for Surgical and Treatment Planning in IDH-Wildtype Glioblastoma (SINUE)
The goal of this clinical trial is to validate ONCOhabitats, an advanced imaging software, as a medical device for the clinical management of IDH-wildtype glioblastoma.
- Trial name
- SINUE (NCT07111195)
- Testing
- The ONCOhabitats software for MRI-based habitat segmentation
- Where
- 5 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Juan M Garcia-Gomez
Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients…
- Trial name
- NCT07544992
- Testing
- Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Primary Glioblastoma Multiforme
Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme
The purpose of this research study is to determine if combining all three treatments of Gliadel wafers, Temozolomide and Radiation therapy at the same time is safe and more effective than one treatment at a time.
- Trial name
- Temodar (NCT00574964)
- Testing
- Gliadel Wafer, Temodar and Radiotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Iowa
Glioblastoma
Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma
After surgery, a key step in treatment of patients diagnosed with glioblastoma (high grade brain tumour) is radiotherapy. The ideal clinical target volume (CTV) for radiotherapy treatment planning includes all tumour cells…
- Trial name
- PhysMRRT (NCT05970757)
- Testing
- Extended MRI
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Erasmus Medical Center
Glioblastoma, Adult-type Diffuse Gliomas
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating…
- Trial name
- FIGHT-209 (NCT05267106)
- Testing
- Pemigatinib
- Where
- 79 sites in United States, Denmark and 7 more
- Volunteers
- 83 people
- Sponsor
- Incyte Corporation
Astrocytoma, Grade IV
ALBATROSS Study: International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated at Vascular Habitats of High-grade Gliomas
This Clinical study is framed in the ALBATROSS Project: Clinically validated decision support system based on pixel level Artificial Intelligent models for deciding treatment in glioblastoma.
- Trial name
- ALBATROSS (NCT05229198)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Juan M Garcia-Gomez
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma.
- Trial name
- NCT05879250
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Northwestern University
Glioblastoma, High-grade Glioma
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients.
- Conditions
- Glioblastoma, High-grade Glioma, Glioblastoma, IDH-wildtype, Glioblastoma, IDH-mutant
- Trial name
- SUPRAMAX (NCT06118723)
- Testing
- Supramaximal resection, Maximal safe resection
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 784 people
- Sponsor
- Jasper Gerritsen
IDH Family Wildtype, Recurrent Anaplastic Astrocytoma
Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
This phase II trial studies how well laser interstitial thermal therapy and lomustine work in treating patients with glioblastoma or anaplastic astrocytoma that has come back.
- Conditions
- IDH Family Wildtype, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma
- Trial name
- NCT03022578
- Testing
- Laser Interstitial Thermal Therapy, Lomustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, Glioblastoma, IDH-wildtype
Biomolecular Analysis for Predicting Response to Regorafenib
The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.
- Trial name
- RegoRec (NCT05759195)
- Testing
- Biomolecular tumor analysis
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Primary Glioblastoma
AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM
This is a multi-center, double-blind, 2:1 randomized phase III trial to determine whether the addition of AV-GBM-1, a therapeutic, patient-specific dendritic cell vaccine, to standard therapy increases OS of patients with a…
- Trial name
- NCT05100641
- Testing
- AV-GBM-1, Autologous monocytes
- Volunteers
- 672 people
- Sponsor
- Aivita Biomedical, Inc.
Glioblastoma, IDH-wildtype
Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
Tailored approaches targeting crucial oncogenes and pathways have shown successful results in a number of cancer types and offer exciting perspective in neuro-oncology.
- Trial name
- OPTIMUM (NCT04945148)
- Testing
- Metformin, Radiation IMRT, Temozolomide
- Where
- 7 sites in France, Italy
- Volunteers
- 640 people
- Sponsor
- Hopital Foch
Glioblastoma, Mismatch Repair Deficiency
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency
Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma with Mismatch Repair Deficiency.
- Trial name
- NCT07385846
- Testing
- Pembrolizumab, Navifus Focused Ultrasound Sonification
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jennifer Leddon
IDH Wild Type Glioblastoma
Feasibility of FMISO in Brain Tumors
This phase II trial studies how well 18F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors.
- Trial name
- NCT03649880
- Testing
- ¹⁸F-Fluoromisonidazole, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- OHSU Knight Cancer Institute
Glioblastoma, Malignant Glioma
Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics
The purpose of this study is to determine whether Q cells separated from the glioma sample are determinants in treatment response and prognosis of glioma patients
- Trial name
- NCT02047058
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanfang Hospital, Southern Medical University